Home » Clinical Trials » Solid tumors » NCT05472857
NCT05472857

Clinical Study of CLDN18.2-targeting Chimeric Antigen Receptor-modified Autologous T Cells in Advanced Solid Tumors With Positive CLDN18.2 Expression

Study Summary

This is an open label, multi-center, Phase 1 clinical trial to evaluate the safety and efficacy of autologous claudin18.2 chimeric antigen receptor T-cell therapy in advanced solid tumors with positive CLDN18.2 expression

Interested in this trial?

Submit an Inquiry

Interventions

Claudin 18.2 CAR-TBIOLOGICAL
treatment with anti-claudin18.2 chimeric antigen receptor T-cell infusion

Study Locations

FacilityCityStateCountry
Changhai HospitalShanghaiShanghai MunicipalityChina

Official Trial Information

View on ClinicalTrials.gov

Data sourced from ClinicalTrials.gov. Last updated: May 29, 2026